|Last Update: 05/23/13 - 4:00 PM EDT|
|YTD Performance: 57.39%|
|Previous Close: $123.44|
|52 Week Range: $58.53 - $131.82|
|Oustanding Shares: 417,122,477|
|Market Cap: 51,514,625,910|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||4||4||4||4|
|Growth Rate (Year over Year)||16.74%||8.61%||18.61%||21.73%|
Shares of CELG now seen reaching $80, Jefferies said. Estimates also raised on strong earnings. Buy rating.
CELG was upgraded from Hold to Buy, Argus Research said. $75 price target. Stock appears oversold, following a 20% decline.
Argus upgrades CELG to Buy from Hold and sets target price at $75 saying the shares have fallen more than 20% from their 52-week on April 3, most recently on a negative pipeline announcement for Revlimid. However, they do not expect this setback to have a 20% impact on earnings.
Keep an eye on the greenback, as it may soon resume its longer-term rally.
Shares of CELG now seen reaching $75, Jefferies said. Estimates also lowered on approval delay. Buy rating.
Shares of CELG now seen reaching $75, according to Morgan Stanley. Estimates also reduced, given disappointing trial data for Revlimid. Overweight rating.
It is now imperative that Celgene show growth away from Revlimid.
If you're a risk-taker, you may want to pick this up on a trigger.
Celgene’s shares have dropped since a disappointing report, but this growth story is far from broken.
Declines can be opportunities, but not all declines are opportunities.
Shares of CELG now seen reaching $85, UBS said. Estimates also lowered to reflect pricing and collection headwinds. Buy rating.